Quarterly ResultAug 13, 2026, 08:29 AM
Lucid Diagnostics Q2 Revenue $1.5M; Net Loss $14.7M
AI Summary
Lucid Diagnostics Inc. reported its second quarter 2026 financial results, with EsoGuard revenue reaching $1.5 million and 2,770 EsoGuard tests processed. The company posted a GAAP net loss of $14.7 million, or $(0.08) per common share, and a non-GAAP adjusted loss of $10.9 million. Key business updates include securing a commercial coverage policy for EsoGuard from Concert and developing a health economic cost-effectiveness model to support payor engagement.
Key Highlights
- Lucid Diagnostics recognized $1.5 million in EsoGuard revenue for Q2 2026.
- The company processed 2,770 EsoGuard® Esophageal DNA Tests in Q2 2026.
- GAAP net loss attributable to common stockholders was $14.7 million, or $(0.08) per common share.
- Non-GAAP adjusted loss for Q2 2026 was $10.9 million, or $(0.06) per common share.
- Operating expenses for the quarter were approximately $14.3 million.
- Lucid secured a commercial coverage policy for EsoGuard from Concert, a laboratory benefit manager.
- Cash and cash equivalents stood at $33.4 million as of June 30, 2026.
Price Impact
More from LUCD